Stachydeoma graveolens

Stachydeoma graveolens works primarily through its active compounds, specifically pulegone and isomenthone. These volatile oils act on smooth muscle tissue and the central nervous system. Pulegone is known to stimulate uterine contractions, which explains the herb's traditional applications but also its potential toxicity. The presence of flavonoids contributes to the plant's antimicrobial properties, though clinical evidence remains limited (Evidence Level C).

No, Stachydeoma graveolens is considered unsafe during pregnancy. The herb contains pulegone, a compound known to stimulate uterine smooth muscle, which can lead to contractions and potential miscarriage. Consequently, it is strictly contraindicated for pregnant women. Women who are breastfeeding should also avoid this herb due to the lack of safety data and potential risks to the infant.

The traditional adult dosage for Stachydeoma graveolens is prepared as a tea using one teaspoon of dried herb per cup of boiling water. This infusion is typically taken twice daily. Because the herb contains pulegone, which can cause toxicity at high doses, usage should be restricted to short durations and avoided by children.

While specific clinical trials are lacking (Evidence Level C), Stachydeoma graveolens may theoretically interact with medications metabolized by the liver. The presence of pulegone suggests potential interactions with drugs that affect the central nervous system or hepatotoxic medications. Patients taking prescription medications should consult a healthcare provider before use, as the herb may alter drug metabolism.

Traditionally, Florida Native Americans utilized Stachydeoma graveolens for reducing fevers and treating respiratory conditions. In folk medicine, the herb is valued as an insect repellent due to its strong, pennyroyal-like fragrance. While antimicrobial properties have been suggested, these uses are supported by traditional knowledge and preliminary phytochemical analysis rather than rigorous clinical trials (Evidence Level C).